Dr. Forster Discusses the ATLANTIS Study in Small-Cell Lung Cancer

Martin Forster, MD
Published: Wednesday, Oct 04, 2017



Martin Forster, MD, medical oncologist, University College London Hospitals, discusses the ATLANTIS study in small-cell lung cancer (SCLC).

The ongoing ATLANTIS trial is investigating lurbinectedin (PM01183) plus doxorubicin versus cyclophosphamide, doxorubicin and vincristine or topotecan in patients with SCLC.

Initial responses have been seen with lurbinectedin as a single agent in patients with platinum-sensitive patients.
 


Martin Forster, MD, medical oncologist, University College London Hospitals, discusses the ATLANTIS study in small-cell lung cancer (SCLC).

The ongoing ATLANTIS trial is investigating lurbinectedin (PM01183) plus doxorubicin versus cyclophosphamide, doxorubicin and vincristine or topotecan in patients with SCLC.

Initial responses have been seen with lurbinectedin as a single agent in patients with platinum-sensitive patients.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x